<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7401.38943 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/6/2020 8:09:43 PM -->
      <!-- iXBRL Library version: 1.0.7401.38955 -->
      <!-- iXBRL Service Job ID: 428cfdf5-ffa0-447d-9620-8f211e708d97 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:edit="http://www.editasmedicine.com/20200805" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:EntityCentralIndexKey" id="Tc_Yp1STzYkXkmd_6n7Bw2lKw_2_1">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:AmendmentFlag" id="Tc_FUkkI4jdr0qSJYynWemqHA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="edit-20200805.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:15.52pt;"><a id="_a53d1400_ac63_4ff3_abb5_9b3afe0391ac"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:DocumentType" id="Narr_Xb1R6ZLmKUi-yyEZ6oR8QQ">8-K</ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:9pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT<br />Pursuant to Section&#160;13 or 15(d)<br />of The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_Cm1ly_r24USzaSdp9AUd-Q"><span style="font-size:10pt;">August 5, 2020</span></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:EntityRegistrantName" id="Narr_QqVsa9aK6k6MKJ2VgDrn9Q">Editas Medicine, Inc.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">(Exact Name of Registrant as Specified in its Charter)</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"><a id="_749abe8c_be64_4b17_a2ec_1ba8d064c547"></a><a id="Tc_B40IJSorZUa3WbPGBzp38A_2_0"></a><a id="Tc_dSuDD602vkOo-OpQ9TKemg_2_1"></a><a id="Tc_iLgSHI9WhkabuQOXJiXhvA_2_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_zryUdKXgUkiDeeU1if7sFw_1_0"><b style="font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:EntityFileNumber" id="Tc_Em6WAJ2BxEyGN7Q37cj1zw_1_1"><b style="font-size:10pt;font-weight:bold;">001-37687</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:EntityTaxIdentificationNumber" id="Tc_0A7_df16GU6qIrNJQmVQtA_1_2"><b style="font-size:10pt;font-weight:bold;">46-4097528</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation)</p></td><td style="vertical-align:top;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9fc645df_45fc_468e_93c2_2a55b7bda50a"></a><a id="Tc_8dQjRJua0UuLW-RrMKiU4g_1_0"></a><a id="Tc_ofm_-2vCy0KNMPXTqM8Qvg_2_0"></a><a id="Tc_H3-a6g9Mk06APojGEFCVcA_2_1"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:EntityAddressAddressLine1" id="Narr_JmDvEofrdkWLmzXnswnmng"><b style="font-size:10pt;font-weight:bold;">11 Hurley Street</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:EntityAddressCityOrTown" id="Narr_m-tJB3p2o02KKjZWrAlltg"><b style="font-size:10pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_huqO2nw6ok2ry89L47P5kg"><b style="font-size:10pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:EntityAddressPostalZipCode" id="Tc_70mxnn_ol0GPqBbc7qVFWA_1_1"><b style="font-size:10pt;font-weight:bold;">02141</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:45.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;</span><b style="font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:CityAreaCode" id="Narr_7bhuifEbz06X67P0TU_u4A"><b style="font-size:10pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:LocalPhoneNumber" id="Narr_NK3SS5fR-k6lIzqj-qWdag"><b style="font-size:10pt;font-weight:bold;">401-9000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction&#160;A.2. below):</p><a id="_03954c9c_0f6f_44ac_b87d_250785e27b4e"></a><a id="Tc_fMNR1WoP_0q7XVho9JXH3Q_2_1"></a><a id="Tc_773WUGsL7kCbJ-Z-GSGHzg_4_1"></a><a id="Tc_BCR17zDFDke0o2CPIQQvTA_6_1"></a><a id="Tc_Xt-08qTKlEGGDqRKkLldpw_8_1"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_7rHKvAJqCk24nMiPIMljaA_2_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17&#160;CFR&#160;230.425)</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_-OjhktCKKkyC2hD4pwFD1Q_4_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17&#160;CFR&#160;240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_eSr2XTIgi0eexEaEcnPQgQ_6_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17&#160;CFR&#160;240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_X9D1ctqRNki8sWBd71Jtkw_8_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_dcb8c928_e46c_434f_a26a_0d9cf6b41806"></a><a id="Tc_Nk6bVv5QRE6l0CR301w_dg_1_0"></a><a id="Tc_6VQ-ai5w0UeV77OixzLUjA_1_1"></a><a id="Tc_fOG51vFgRE6ZMUcC-067NA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:11.8pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:17.65pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:Security12bTitle" id="Tc_DoWF7dqWG0WLXASOS-_XoA_2_0"><span style="font-size:8pt;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" name="dei:TradingSymbol" id="Tc_dNMZnid4D0K4PiicwkS8-Q_2_1"><span style="font-size:8pt;">EDIT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_svJep9V_I0OjhuZ_8FFy1w_2_2"><span style="font-size:8pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-<span style="white-space:pre-wrap;">2 of this chapter).    </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Emerging growth company&#160;</span><ix:nonNumeric contextRef="Duration_8_5_2020_To_8_5_2020_EpipbXwq402W9mzn0o8rMg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_rHMLkGfAVEihAf8HT-HB0A"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;border-bottom:2.25pt double #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;">&#160;</p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_28b5ad88_3cef_469f_8a2d_89dd1fccecde"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On August 5, 2020, Editas Medicine, Inc. (the &#8220;Company&#8221;) and Allergan Sales, LLC (&#8220;Allergan Sales&#8221;) an affiliate of Allergan Pharmaceuticals International Limited (&#8220;APIL&#8221; and collectively with Allergan Sales, &#8220;Allergan&#8221;) entered into a termination agreement (the &#8220;Termination Agreement&#8221;) pursuant to which, among other things, the Company and Allergan agreed to terminate, effective as of August 5, 2020, (i) the Strategic Alliance and Option Agreement, dated March 14, 2017, by and between the Company and APIL (the &#8220;Collaboration Agreement&#8221;) and (ii) the Co-Development and Commercialization Agreement, dated as of February 22, 2019, by and between Allergan and Editas (the &#8220;Profit Sharing Agreement&#8221;).  AbbVie, Inc. acquired Allergan in May 2020 and the termination was mutually agreed upon by the parties pursuant to the terms described herein.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Pursuant to the Termination Agreement, the Company has regained full global rights to research, develop, manufacture, and commercialize its ocular product candidates, including EDIT-101 for the treatment of Leber congenital amaurosis 10 (&#8220;LCA10&#8221;).   Under the Termination Agreement, Allergan has granted the Company a non-exclusive, royalty-bearing right and license, including the right to grant sublicenses (through multiple tiers), to certain Allergan know-how that is necessary to develop, manufacture and commercialize EDIT-101.  In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize a product directed to each of four collaboration targets, one of which is LCA10.  Under the Termination Agreement, the Company is obligated to make a payment to Allergan, as well as certain payments based on the achievement of clinical and regulatory milestones for each target program, aggregated sales milestones for all products covered by the Termination Agreement, and pay royalties on net sales.  The parties also agreed to enter into a transition services agreement to facilitate the transfer of the LCA10 program to the Company and to terminate a master services agreement previously entered into by and between the Company and APIL.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In March 2017, the Company and APIL entered into the Collaboration Agreement to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders.  Over the research term of the Collaboration Agreement, Allergan had an exclusive option to exclusively license from the Company worldwide rights to up to five collaboration development programs for the treatment of ocular disorders, including the Company&#8217;s LCA10 program and the related experimental therapeutic EDIT-101 to treat LCA10.  In July 2018, Allergan exercised its option to develop and commercialize the Company&#8217;s EDIT-101 product candidate and in 2019 the Company and Allergan initiated a Phase 1/2 clinical trial of EDIT-101 for the treatment of LCA10.  The Company and Allergan subsequently entered into the Profit Sharing Agreement under which the parties agreed to co-develop and equally split profits and losses for EDIT-101 in the United States.  Under the Collaboration Agreement, the Company has received an initial upfront payment, an option exercise payment and a milestone payment and was eligible for clinical, regulatory, launch, and commercial milestone payments, as well as royalties on the sale of products covered by the Collaboration Agreement in countries in which the parties were not sharing profits.  The foregoing is only a brief description of the material terms of the Collaboration Agreement and the Profit Sharing Agreement and is qualified in its entirety by reference to the Collaboration Agreement and the Profit Sharing Agreement that were filed as Exhibit 10.32 and Exhibit 10.33, respectively, to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities Exchange Commission on February 26, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 1.02  Termination of Material Definitive Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 1.02 by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</b></p><a id="_Hlk535744647"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">On August 6, 2020, the Company issued a press release announcing financial results for the fiscal quarter ended June 30, 2020 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;Filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.45pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:87.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.09%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />No.</b></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:87.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a href="edit-20200805xex99d1.htm"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:none;">Press release issued by the Company on August 6, 2020*</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">*&#160;&#160;&#160;This exhibit shall be deemed to be furnished and not filed.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><a id="_a71d0d02_9358_417c_b1f4_f328df83896e"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:26.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:16.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:18.45pt;"><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:39.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EDITAS MEDICINE, INC.</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:39.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 6, 2020</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:26.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Michelle Robertson</span></p></td><td style="vertical-align:top;width:16.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michelle Robertson<br />Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "edit-20200805x8k.htm", "description": "8-K", "secsgml_size_bytes": 42686}]
{"company-data": {"conformed-name": "Editas Medicine, Inc.", "cik": "0001650664", "assigned-sic": "2836", "irs-number": "464097528", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37687", "film-number": "201081680"}, "business-address": {"street1": "11 HURLEY ST.", "city": "CAMBRIDGE", "state": "MA", "zip": "02141", "phone": "617-401-9000"}, "mail-address": {"street1": "11 HURLEY ST.", "city": "CAMBRIDGE", "state": "MA", "zip": "02141"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 5, 2020
Editas Medicine, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-37687
46-4097528
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
​
11 Hurley Street
Cambridge
,
Massachusetts
02141
(Address of Principal Executive Offices)
(Zip Code)
​
Registrant's telephone number, including area code:
(
617
)
401-9000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
EDIT
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-
2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01            Entry into a Material Definitive Agreement
On August 5, 2020, Editas Medicine, Inc. (the "Company") and Allergan Sales, LLC ("Allergan Sales") an affiliate of Allergan Pharmaceuticals International Limited ("APIL" and collectively with Allergan Sales, "Allergan") entered into a termination agreement (the "Termination Agreement") pursuant to which, among other things, the Company and Allergan agreed to terminate, effective as of August 5, 2020, (i) the Strategic Alliance and Option Agreement, dated March 14, 2017, by and between the Company and APIL (the "Collaboration Agreement") and (ii) the Co-Development and Commercialization Agreement, dated as of February 22, 2019, by and between Allergan and Editas (the "Profit Sharing Agreement").  AbbVie, Inc. acquired Allergan in May 2020 and the termination was mutually agreed upon by the parties pursuant to the terms described herein.
Pursuant to the Termination Agreement, the Company has regained full global rights to research, develop, manufacture, and commercialize its ocular product candidates, including EDIT-101 for the treatment of Leber congenital amaurosis 10 ("LCA10").   Under the Termination Agreement, Allergan has granted the Company a non-exclusive, royalty-bearing right and license, including the right to grant sublicenses (through multiple tiers), to certain Allergan know-how that is necessary to develop, manufacture and commercialize EDIT-101.  In addition, the Company is obligated to use commercially reasonable efforts to develop and commercialize a product directed to each of four collaboration targets, one of which is LCA10.  Under the Termination Agreement, the Company is obligated to make a payment to Allergan, as well as certain payments based on the achievement of clinical and regulatory milestones for each target program, aggregated sales milestones for all products covered by the Termination Agreement, and pay royalties on net sales.  The parties also agreed to enter into a transition services agreement to facilitate the transfer of the LCA10 program to the Company and to terminate a master services agreement previously entered into by and between the Company and APIL.
In March 2017, the Company and APIL entered into the Collaboration Agreement to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders.  Over the research term of the Collaboration Agreement, Allergan had an exclusive option to exclusively license from the Company worldwide rights to up to five collaboration development programs for the treatment of ocular disorders, including the Company's LCA10 program and the related experimental therapeutic EDIT-101 to treat LCA10.  In July 2018, Allergan exercised its option to develop and commercialize the Company's EDIT-101 product candidate and in 2019 the Company and Allergan initiated a Phase 1/2 clinical trial of EDIT-101 for the treatment of LCA10.  The Company and Allergan subsequently entered into the Profit Sharing Agreement under which the parties agreed to co-develop and equally split profits and losses for EDIT-101 in the United States.  Under the Collaboration Agreement, the Company has received an initial upfront payment, an option exercise payment and a milestone payment and was eligible for clinical, regulatory, launch, and commercial milestone payments, as well as royalties on the sale of products covered by the Collaboration Agreement in countries in which the parties were not sharing profits.  The foregoing is only a brief description of the material terms of the Collaboration Agreement and the Profit Sharing Agreement and is qualified in its entirety by reference to the Collaboration Agreement and the Profit Sharing Agreement that were filed as Exhibit 10.32 and Exhibit 10.33, respectively, to the Company's Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities Exchange Commission on February 26, 2020.
Item 1.02  Termination of Material Definitive Agreement
The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 1.02 by reference.
Item 2.02              Results of Operations and Financial Condition.
On August 6, 2020, the Company issued a press release announcing financial results for the fiscal quarter ended June 30, 2020 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "Filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
99.1
Press release issued by the Company on August 6, 2020*
104
​
Cover Page Interactive Data File (embedded within the Inline XBRL document)
​
*   This exhibit shall be deemed to be furnished and not filed.
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
​
​
EDITAS MEDICINE, INC.
​
Date:
August 6, 2020
​
By:
/s/ Michelle Robertson
​
​
Michelle Robertson
Chief Financial Officer
​
​
​
​